Virdante is a privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders. Our products incorporate a proprietary `sialic switch` technology to improve the anti-inflammatory properties of antibodies. Dr. Jeffrey Ravetch, a professor at The Rockefeller University and a member of both the National Academy of Sciences and the Institute of Medicine, discovered this novel anti-inflammatory biological pathway and subsequently founded Virdante to develop safer and more effective therapeutic antibodies. Virdante exclusively licensed the technology from The Rockefeller University and established a strategic research alliance with Dr. Ravetch`s laboratory to continue to explore the biology of the sialic switch technology.
Virdante`s leadership team comprises management, board members, investors and advisors with significant experience building and operating successful biopharmaceutical businesses. The leadership team is committed to rapidly achieving human proof of concept for the sialic switch technology by advancing its lead development candidate into the clinic. The company`s business model is to develop and commercialize a proprietary pipeline of biopharmaceuticals and to apply Virdante`s technology to development candidates from a select group of corporate partners.